Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Long-Term Deferred Tax (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 5 years of Long-Term Deferred Tax data on record, last reported at $2.1 million in Q4 2020.

  • For Q4 2020, Long-Term Deferred Tax fell 96.31% year-over-year to $2.1 million; the TTM value through Dec 2020 reached $2.1 million, down 96.31%, while the annual FY2020 figure was $2.1 million, 96.31% down from the prior year.
  • Long-Term Deferred Tax reached $2.1 million in Q4 2020 per LCTX's latest filing, down from $56.3 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $56.3 million in Q4 2019 and bottomed at $49213.0 in Q4 2016.
  • Average Long-Term Deferred Tax over 5 years is $21.2 million, with a median of $8.9 million recorded in 2017.
  • Peak YoY movement for Long-Term Deferred Tax: surged 17984.65% in 2017, then plummeted 96.31% in 2020.
  • A 5-year view of Long-Term Deferred Tax shows it stood at $49213.0 in 2016, then soared by 17984.65% to $8.9 million in 2017, then soared by 332.78% to $38.5 million in 2018, then soared by 46.12% to $56.3 million in 2019, then tumbled by 96.31% to $2.1 million in 2020.
  • Per Business Quant database, its latest 3 readings for Long-Term Deferred Tax were $2.1 million in Q4 2020, $56.3 million in Q4 2019, and $38.5 million in Q4 2018.